منابع مشابه
Growth hormone releasing hormone or growth hormone treatment in growth hormone insufficiency?
Sixteen prepubertal children who were insufficient for growth hormone were treated with growth hormone releasing hormone (GHRH) 1-40 and GHRH 1-29 for a mean time of nine months (range 6-12 months) with each peptide. Eleven children received GHRH 1-40 in four subcutaneous nocturnal pulses (dose 4-8 micrograms/kg/day) and eight (three of whom were also treated with GHRH 1-40) received GHRH 1-29 ...
متن کاملGrowth hormone treatment in non-growth hormone-deficient children
Until 1985 growth hormone (GH) was obtained from pituitary extracts, and was available in limited amounts only to treat severe growth hormone deficiency (GHD). With the availability of unlimited quantities of GH obtained from recombinant DNA technology, researchers started to explore new modalities to treat GHD children, as well as to treat a number of other non-GHD conditions. Although with so...
متن کاملThe Effect of Growth Hormone Based on ELISA Method on the Treatment of Schizophrenic Patients
Background: By studying the types of hormones, the role of genetic and hormonal and chemical agents in schizophrenia can be found. The aim of this study was to determine the effectiveness of Growth Hormone based on ELISA method on the Treatment of Schizophrenic Patients. Methods: This study was a semi-experimental study with pretest-posttest with control group. The study population consisted of...
متن کاملEfficacy and safety of growth hormone treatment for children born small for gestational age
Recombinant growth hormone (GH) is an effective treatment for short children who are born small for gestational age (SGA). Short children born SGA who fail to demonstrate catch-up growth by 2-4 years of age are candidates for GH treatment initiated to achieve catch-up growth to a normal height in early childhood, maintain a normal height gain throughout childhood, and achieve an adult height wi...
متن کاملSafety of growth hormone treatment in pediatric patients with idiopathic short stature.
CONTEXT Recombinant human GH was approved by the United States Food and Drug Administration in 2003 for the treatment of idiopathic short stature (ISS). However, to date, the safety of GH in this patient population has not been rigorously studied. OBJECTIVE The objective of this study was to address the safety of GH treatment in children with ISS compared with GH safety in patient populations...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Research in Pediatric Endocrinology
سال: 2009
ISSN: 1308-5735,1308-5727
DOI: 10.4008/jcrpe.v1i1.8